Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10511614 | 0.98 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL7509608 | 0.86 | SIGMAR1 (0.40) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL8560534 | 0.86 | SIGMAR1 (0.40) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL10511691 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL1746181 | 0.81 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL29291192 | 0.81 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL5323661 | 0.81 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL28080594 | 0.81 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL20997961 | 0.80 | SLC6A4 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL13762256 | 0.80 | SLC6A2 (0.36) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119059961-A | Cyclic fatty polyamine compound, preparation method and application thereof, and cyclic fatty polyamine combined solution | 大连理工大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-110691784-B | Compounds for inhibiting MCL-1 protein | 美国安进公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| CN-110691784-A | Compounds that inhibit MCL-1 protein | 美国安进公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-109996824-A | One-component moisture-curable polyurethane composition | 横滨橡胶株式会社 | 2019-07-09 | — | — | CN | disclosed |
| CN-108604073-A | Conductive roll and its manufacturing method | 株式会社普利司通 | 2018-09-28 | — | — | CN | disclosed |
| CN-104968656-B | autotaxin inhibitors | 诺华股份有限公司 | 2017-08-11 | — | — | CN | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| EP-1781743-A1 | WATER-SOLUBLE PRODUCTS HARDENING WITH RADIATION AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-09 | — | — | EP | disclosed |
| CN-1759110-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2006-04-12 | — | — | CN | disclosed |
| WO-2006018136-A1 | WATER-SOLUBLE PRODUCTS HARDENING WITH RADIATION AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018152-A1 | WATER-SOLUBLE, RADIATION-CURABLE PRODUCTS AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-23 | — | — | WO | disclosed |
| EP-1599519-A1 | METHOD FOR PRODUCING AQUEOUS POLYURETHANE DISPERSIONS IN MINIEMULSION AND IN THE PRESENCE OF A CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076516-A1 | METHOD FOR PRODUCING AQUEOUS POLYURETHANE DISPERSIONS IN MINIEMULSION AND IN THE PRESENCE OF A CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-5714470-A | PENTAFLUORO ALKYL TERMINATED PEPTIDE DERIVATIVES; TREATMENT OF INFLAMMATORY DISEASES, EMPHYSEMA AND CHRONIC BRONCHITIS | MERRELL PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5693619-A | ENZYME INHIBITORS; ADMINISTERED TO TREAT CONGESTIVE HEART FAILURE AND HYPERTENSION | BOEHRINGER INGELHEIM (CANADA), LTD. (CA) | 1997-12-02 | — | — | US | disclosed |
| US-4889857-A | BACTERICIDES; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| EP-0311948-A2 | Quinolonecarboxylic acid compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | SLC6A2 91/4885SLC6A3 100/4885SLC6A4 80/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SLC6A2 158/4885SLC6A3 93/4885SLC6A4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.